• BECOME A MEMBER
  • MEMBER LOG IN
  • FIND A CLINIC
  • ru
    • en
    • es
    • fr
    • da
    • it
    • cs
    • pl
    • nl
    • no
    • sv
    • pt
    • de
  • EHDN and
    Enroll-HD 2024
  • ABOUT HD
  • ABOUT EHDN
  • NEWS & EVENTS
  • HD Patients and Families
    • HD Patients and Families Home
    • Living with HD
    • Finding Clinics and Support
    • HD Research
  • HD Clinicians and Researchers
    • HD Clinicians and Researchers Home
    • Previous & Ongoing Research
    • Publications
    • EHDN Working Groups
    • Rater training and certification
    • Seed Fund Applications
    • Data-Mining Applications
    • Fellowship programme
    • Grant Management & Collaborations
  • Clinical Trial Sponsors
    • Clinical Trial Sponsors Home
    • Feasibility Assessment
    • Protocol Advice
    • Operational Support
    • Recruitment
    • Clinical Rater Training
    • HD Clinical Trial Site Certification Scheme
  • About Huntington's Disease
  • About EHDN
    • EHDN Structure
    • EHDN Working Groups
    • Grant Management & Collaborations
    • HD Clinics
    • Previous & Ongoing Research
    • Resources and Services
  • News & Events
  • REGISTRY LOGIN
  • MEMBER LOG IN
  • Find a Clinic
Skip to content
European Huntington's Disease Network
  • HD Patients and Families
    • Patients & Families Home
    • Living with HD
    • Finding Clinics and Support
    • HD Research
  • HD Clinicians and Researchers
    • Clinicians & Researchers Home
    • HD Science Think Tank
    • EHDN Working Groups
    • Fellowship programme
    • Seed Fund Applications
    • Grant management & Collaborations
    • Data-Mining Applications
    • Rater training and certification
    • Research & Publications
    • Guidelines
  • Clinical Trial Sponsors
    • Clinical Trial Sponsors Home
    • Protocol Advice
    • Feasibility Assessment
    • Operational Support
    • Recruitment
    • Clinical Rater Training
    • Site Certification Scheme

Рубрика: Uncategorized

Project: Measuring the Daily Stressors of Young People Affected by Huntington’s Disease

Posted on Май 4, 2021 by Lisanne Muetze

This study is examining what parts of daily life are stressful for young people affected by HD. To understand this, we are asking young people from HD families to share their thoughts on the aspects of their life that are stressful or concerning, such as their family and social relationships, and daily functioning. […]

Read More…

EHDN statement on the discontinuation of the phase 1b/2a trials PRECISION HD1 and PRECISION HD2

Posted on Апрель 12, 2021 Edited Апрель 12, 2021 by Lisanne Muetze

Wave Life Sciences announced on Monday 29th March 2021 that it will discontinue development of two of their three Huntingtin lowering ASO drugs as analysis of the phase 1b/2a trials PRECISION HD1 and PRECISION HD2 showed no evidence of a dose response across the dose levels tested. […]

Read More…

16th Annual Huntington’s Disease Therapeutics Conference: A Forum for Drug Discovery & Development

Posted on Март 31, 2021 Edited Март 31, 2021 by Lisanne Muetze

CHDI is delighted to announce that the 16th Annual HD Therapeutics Conference will be a fully online, virtual experience to be held April 27-29, 2021. The conference program is currently being crafted and will cover all aspects of drug discovery and development for Huntington’s disease. […]

Read More…

Huntington’s Australian National Conference 2021

Posted on Март 30, 2021 Edited Март 31, 2021 by Lisanne Muetze

Huntington’s NSW ACT is very pleased to announce it will be hosting the next national HD conference as a series of virtual events from 25 May – 1 June 2021. […]

Read More…

EHDN statement on the discontinuation of the GENERATION HD1 trial

Posted on Март 29, 2021 Edited Март 31, 2021 by Lisanne Muetze

On Monday 22 March 2021 Roche announced that dosing is being permanently discontinued in the GENERATION HD1 phase III trial evaluating the effect of tominersen, an ASO-based huntingtin lowering drug on the clinical course of HD. Dosing is also being paused on the open label extension study, GEN-EXTEND. This decision is the outcome of a […]

Read More…

Discontinuation of the GENERATION HD1 trial «Tominersen programme update — Community letter»

Posted on Март 23, 2021 Edited Март 23, 2021 by Lisanne Muetze

[…]

Read More…

Amendments to the EHDN Constitution 2021

Posted on Март 16, 2021 by Lisanne Muetze

The comment period for the amendments to the EHDN Constitution is now open. […]

Read More…

HDYO’s International Young Adult Virtual Congress

Posted on Март 15, 2021 by Lisanne Muetze

Supporting young people, all over the world, impacted by Huntington’s disease. […]

Read More…

In Memory of Prof. Marina Frontali

Posted on Март 3, 2021 Edited Март 3, 2021 by Lisanne Muetze

In memory of Prof. Marina Frontali, who sadly passed away due to COVID-19. […]

Read More…

EHDN Newsletter – 42nd edition

Posted on Март 1, 2021 Edited Март 3, 2021 by Katrin Barth

The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]

Read More…

Навигация по записям

Предыдущие записи
Следующие записи

Subscribe to
EHDN news

* Denotes required field
  • © EHDN 2016
  • Terms of Use
  • Privacy Policy
  • Contact EHDN
  • University of Ulm
LinkedIn